-

ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL

WOIPPY, France--(BUSINESS WIRE)--Regulatory News:

ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the French Financial Markets Authority (AMF) via ONDE, the centralized information filing system, regarding the sale of a new block of ABL Diagnostics shares as part of an over-the-counter transaction with a private third party.

The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1092130.

With the support of its main shareholder, ABL, ABL Diagnostics is continuing its efforts to enhance its visibility among all stakeholders (investors, partners, customers, and employees).

About ABL Diagnostics (ABLD)

ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:

  • Molecular polymerase chain reaction (PCR) detection – UltraGene, and
  • Genotyping by DNA sequencing – DeepChek®.

ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.

ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.

An expanding portfolio of microbiology products:

  • HIV – Drug resistance testing, including a whole genome kit.
  • SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.
  • Microbiome and taxonomy – 16s/18s RNA-based analyses.
  • Other viral and bacterial targets – Comprehensive molecular assays.

Integrated Solutions

  • Real-time syndromic PCR tests
  • Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.
  • MediaChek® – Clinical Sample Collection Kits.

ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.

Contacts

ABL Diagnostics SA

Tel : +33 (0)7 83 64 68 50
Email : info@abldiagnostics.com
https://www.abldiagnostics.com/

ABL Diagnostics

BOURSE:ABLD
Release Versions
EnglishFrench

Contacts

ABL Diagnostics SA

Tel : +33 (0)7 83 64 68 50
Email : info@abldiagnostics.com
https://www.abldiagnostics.com/

More News From ABL Diagnostics

ABL Diagnostics Update Regarding Non-Binding Letter of Intent

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics S.A. (Euronext: ABLD – ISIN: FR001400AHX6) informs the market that the non-binding Letter of Intent entered into between ProPhase Labs, Inc. and Advanced Biological Laboratories S.A. (“ABL S.A.”) has expired and the parties are no longer pursuing the proposed transaction. The Letter of Intent was preliminary and non binding. Certain customary provisions continue to apply, which ABL will continue to honor. No additional informatio...

ABL SA Executes the First Purchase Notice of ABL Diagnostics Shares With Alumni Capital

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ISIN: FR001400AHX6 – Euronext Paris ABL Diagnostics SA (“the Company”) (Paris:ABLD) informs the public that its principal shareholder, Advanced Biological Laboratories SA (ABL SA), has executed a first Purchase Notice under the Share Disposal and Share Loan Agreement signed on 16 October 2025 with Alumni Capital LP (Delaware, USA) and Alumni Capital Limited (British Virgin Islands). In this context, 128,026 existing ABL Diagnostics shares have b...

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

WOIPPY, France--(BUSINESS WIRE)--Regulatory News:  ABL Diagnostics (Euronext: ABLD - ISIN: FR001400AHX6) informs its shareholders and the market that Advanced Biological Laboratories S.A. (“ABL S.A.”), its controlling shareholder, and ProPhase Labs, Inc. (“ProPhase,” Nasdaq: PRPH) have signed a non‑binding letter of intent (the “LOI”) regarding a proposed reverse merger pursuant to which ABL would become the majority owner of the combined company. The LOI is preliminary and creates no obligatio...
Back to Newsroom